Ocular biomarkers of Alzheimer’s disease

Central Nervous System Agents in Medicinal Chemistry

Volumn 15, Issue 2, 2015, Pages 117-125

  Heaton, George R ^a   Davis, Benjamin M ^a   Turner, Lisa A ^a   Cordeiro, Maria F ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer s; Biomarker; Diagnosis; Ocular; Pathology; Retina

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN; CHRM4 PROTEIN, HUMAN; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; MYDRIATIC AGENT; TROPICAMIDE;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHOROID; COGNITION; CONTRAST SENSITIVITY; FLUORESCENCE; HUMAN; LENS; MEMORY; MOTOR PERFORMANCE; NERVE CELL NETWORK; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; PUPIL DISEASE; RETINA; RETINA BLOOD FLOW; RETINAL NERVE FIBER LAYER THICKNESS; SCANNING LASER OPHTHALMOSCOPY; SENILE PLAQUE; VISUAL FIELD; VISUAL INFORMATION; ANIMAL; CHEMISTRY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; EARLY DIAGNOSIS; MOUSE; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGICAL REFLEX; PATHOLOGY; PUPIL REFLEX; RETINA BLOOD VESSEL; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CHOROID; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; LENS, CRYSTALLINE; MICE; MICE, TRANSGENIC; MUSCARINIC ANTAGONISTS; MYDRIATICS; NEUROFIBRILLARY TANGLES; RECEPTORS, MUSCARINIC; REFLEX, ABNORMAL; REFLEX, PUPILLARY; RETINA; RETINAL VESSELS; TOMOGRAPHY, OPTICAL COHERENCE; TROPICAMIDE;

EID: 84930709186     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/1871524915666150319123015     Document Type: Article

References (114)

1. Martin, P.; Emiliano, A.; Guerchet, M.; Prina, M. World Alzheimer Report 2014 Dementia and Risk Reduction. Alzheimer’s Dis. Int., 2014.
2. Ferri, C.P.; Prince, M.P.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, P.R.; Rimmer, E.; Scazufca, M. Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366, 2112-2117.
3. Prince, M. World Alzheimer Report 2014 Dementia and Risk Reduction. Alzheimer’s Dis. Int., 2014.
4. Matthews, F. E.; Arthur, A.; Barnes, L. E.; Bond, J.; Jagger, C.; Robinson, L.; Brayne, C. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: Results of the cognitive function and ageing study i and II. Lancet, 2013, 382, 1405-1412.
5. Prince, M.; Jackson, J. World Alzheimer Report, 2009, 2009, p. 14.
6. Perl, D. P. Neuropathology of Alzheimer’s Disease. Mt Sinai J. Med., 2010, 77, 32-42.
7. Alzheimer’s Society UK. Dementia UK: Update. Dement. UK, 2014.
8. Hampel, H.; Frank, R.; Broich, K.; Teipel, S. J.; Katz, R. G.; Hardy, J.; Herholz, K.; Bokde, A. L. W.; Jessen, F.; Hoessler, Y. C.; Sanhai, W. R.; Zetterberg, H.; Woodcock, J.; Blennow, K. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov., 2010, 9, 560-574.
9. Chafekar, S. M.; Baas, F.; Scheper, W. Oligomer-specific Abeta toxicity in cell models is mediated by selective uptake. Biochim. Biophys. Acta, 2008, 1782, 523-531.
10. Sakono, M.; Zako, T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J., 2010, 277, 1348-1358.
11. Ferreira, S. T.; Vieira, M. N. N.; De Felice, F. G. Soluble protein oligomers as emerging toxins in Alzheimer’s and other amyloid diseases. IUBMB Life, 2007, 59, 332-345.
12. Leung, K. K.; Bartlett, J. W.; Barnes, J.; Manning, E. N.; Ourselin, S.; Fox, N. C. Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. Neurology, 2013, 80, 648-654.
13. Mattson, M. P. Pathways towards and away from Alzheimer’s disease. Nature, 2004, 430, 631-640.
14. Serrano-Pozo, A.; Frosch, M. P.; Masliah, E.; Hyman, B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med., 2011, 1, a006189.
15. Crews, L.; Masliah, E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum. Mol. Genet., 2010, 19, R12-R20.
16. Whitehouse, P. J.; Price, D. L.; Strumble, R. G.; Clark, A. W.; Coyle, J. T.; Delon, M. R. Alzheimer’s Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain. Science (80-.). 1982, 215, 1237-1239.
17. Parihar, M.S.; Brewer, G.J.J. Amyloid-β as a modulator of synaptic plasticity. Alzheimers. Dis., 2010, 22, 741-763.
18. Shankar, G. M.; Bloodgood, B. L.; Townsend, M.; Walsh, D. M.; Selkoe, D. J.; Sabatini, B. L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci., 2007, 27, 2866-2875.
19. Li, S.; Hong, S.; Shepardson, N. E.; Walsh, D. M.; Selkoe, D. Soluble oligomers of amyloid β-protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron, 2009, 62, 788-801.
20. Snyder, E. M.; Nong, Y.; Almeida, C. G.; Paul, S.; Moran, T.; Choi, E. Y.; Nairn, A. C.; Salter, M. W.; Lombroso, P. J.; Gouras, G. K.; Greengard, P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci., 2005, 8, 1051-1058.
21. Kamenetz, F.; Tomita, T.; Hsieh, H.; Seabrook, G.; Borchelt, D.; Iwatsubo, T.; Sisodia, S.; Malinow, R. Neuron, 2003, 37, 925-937.
22. Morkuniene, R.; Cizas, P.; Jankeviciute, S.; Petrolis, R. J. Oligomer-Induced Membrane Depolarization of Neuronal and Microglial Cells: Role of N-Methyl-D-Aspartate Receptors. Neurosci. Res., 2015, 486, 475-486.
23. Wood, W. G.; Eckert, G. P.; Igbavboa, U.; Müller, W. E. Amyloid beta-protein interactions with membranes and cholesterol: Causes or casualties of Alzheimer’s disease. Biochim. Biophys. Acta - Biomembr., 2003, 1610, 281-290.
24. Mohsenzadegan, M.; Mirshafiey, A. The Immunopathogenic Role of Reactive Oxygen Species in Alzheimer Disease. Iran J Allergy Asthma Immunol., 2012, 11, 203-216.
25. Barnham, K. J.; Masters, C. L.; Bush A. I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 2004, 3, 205-214.
26. Butterfield, Amyloid β-peptide (1-42)-induced Oxidative Stress and Neurotoxicity: Implications for Neurodegeneration in Alzheimer’s Disease Brain. A Review, A. Free Radic. Res., 2002, 36, 1307-1313.
27. Uttara, B.; Singh, A. V; Zamboni, P.; Mahajan, R. T. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol., 2009, 7, 65-74.
28. Praticò, D.; Clark, C. M.; Liun, F.; Rokach, J.; Lee, V. Y.-M.; Trojanowski, J. Q. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol., 2002, 59, 972-976.
29. Working, N.; Haruhiko, G.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G. M.; Cooper, N. R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B. L.; Finch, C. E.; Frautschy, S.; Griffin, W. S. T.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L. F.; Mrak, R.; Mackenzie, I. R.; Mcgeer, P. L.; Banion, M. K. O.; Pachter, J.; Pasinetti, G.; Salaman, C. P.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Muiswinkel, F. L. Van; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Coray, T. W. Inflammation and Alzheimer’ s disease. Neurobiol. Aging, 2000, 21, 383-421.
30. Rubio-Perez, J. M.; Morillas-Ruiz, J. M. A review: inflammatory process in Alzheimer’s disease, role of cytokines. Scientific World Journal., 2012, 2012, 756357.
31. Wyss-coray, T.; Rogers, J.; Selkoe, D. J.; Tanzi, R. E.; Nixon, R. Inflammation in Alzheimer Disease — A Brief Review of the Basic Science and Clinical Literature. Cold Spring Harb. Perspect. Med., 2012, Jan, a006346.
32. Bossy-Wetzel, E.; Schwarzenbacher, R.; Lipton, S. A. Molecular pathways to neurodegeneration. Nat. Med., 2004, 10 Suppl, S2-9.
33. Baudic, S.; Barba, G. D.; Thibaudet, M. C.; Smagghe, A.; Remy, P.; Traykov, L. Executive function deficits in early Alzheimer’s disease and their relations with episodic memory. Arch. Clin. Neuropsychol., 2006, 21, 15-21.
34. Perry, R. J.; Hodges, J. R. Attention and executive deficits in Alzheimer’ s disease: A critical review. Brain, 1999, 383-404.
35. McKhann, G. M.; Knopman, D. S.; Chertkow, H.; Hyman, B. T.; Jack, C. R.; Kawas, C. H.; Klunk, W. E.; Koroshetz, W. J.; Manly, J. J.; Mayeux, R.; Mohs, R. C.; Morris, J. C.; Rossor, M. N.; Scheltens, P.; Carrillo, M. C.; Thies, B.; Weintraub, S.; Phelps, C. H. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers. Dement., 2011, 7, 263-269.
36. Olin, J.; Schneider, L. Galantamine for dementia due to Alzheimer’s disease. Chochrane Libr., 2004.
37. Farlow, M. R.; Grossberg, G. T.; Graham, S. M.; Mcdonald, S. Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease, JAMA, 2014, 291, 317-324.
38. Birks, J. Cholinesterase inhibitors for Alzheimer’s disease. Chochrane Libr., 2012.
39. Lewczuk, P.; Mroczko, B.; Fagan, A.; Kornhuber, Advances in Medical Sciences Biomarkers of Alzheimer’s disease and mild cognitive impairment: A current perspective. J. Adv. Med. Sci., 2015, 60, 76-82.
40. Klunk, W. E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D. P.; Bergström, M.; Savitcheva, I.; Huang, G. F.; Estrada, S.; Ausén, B.; Debnath, M. L.; Barletta, J.; Price, J. C.; Sandell, J.; Lopresti, B. J.; Wall, A.; Koivisto, P.; Antoni, G.; Mathis, C. A.; Långström, B. Imaging Brain Amyloid in Alzheimer’s Disease with Pittsburgh Compound-B. Ann. Neurol., 2004, 55, 306-319.
41. Price, J. C.; Klunk, W. E.; Lopresti, B. J.; Lu, X.; Hoge, J. a; Ziolko, S. K.; Holt, D. P.; Meltzer, C. C.; DeKosky, S. T.; Mathis, C. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. A. J. Cereb. Blood Flow Metab., 2005, 25, 1528-1547.
42. Rachakonda, V.; Pan, T.H.; Le, W.D. Biomarkers of neurodegenerative disorders: how good are they? Cell Res., 2004, 14, 347-358.
43. Humpel, C. Identifying and validating biomarkers for Alzheimer’s disease. Trends Biotechnol., 2011, 29, 26-32.
44. Cedazo-Minguez, A.; Winblad, B. Exp. Gerontol., 2010, 45, 5-14.
45. Rosén, C.; Hansson, O.; Blennow, K.; Zetterberg, H. Biomarkers for Alzheimer’s disease and other forms of dementia: clinical needs, limitations and future aspects. Mol. Neurodegener., 2013, 8, 20.
46. Richard, E.; Schmand, B. A; Eikelenboom, P.; Van Gool, W. MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer’s disease in patients with mild cognitive impairment: a diagnostic accuracy study. a. BMJ Open, 2013, 3.
47. Wright, B. L. C.; Lai, J. T. F.; Sinclair, A. J. Cerebrospinal fluid and lumbar puncture: A practical review. J. Neurol., 2012, 259, 1530-1545.
48. Guo, L.; Duggan, J.; Cordeiro, M. Alzheimers Disease and Retinal Neurodegeneration. Curr. Alzheimer Res., 2010, 7, 3-14.
49. Cordeiro, M. F.; Migdal, C.; Bloom, P.; Fitzke, F. W.; Moss, S. E. Imaging apoptosis in the eye. Eye (Lond)., 2011, 25, 545-553.
50. Galvao, J.; Davis, B. M.; Cordeiro, M. F. In vivo imaging of retinal ganglion cell apoptosis. Curr. Opin. Pharm., 2013, 13, 123-127.
51. Cvekl, A.; Tamm, E. R. Anterior eye development and ocular mesenchyme: new insights from mouse models and human diseases. Bioessays, 2004, 26, 374-386.
52. London, A.; Benhar, I.; Schwartz, M. The retina as a window to the brain-from eye research to CNS disorders. Nat. Rev. Neurol., 2013, 9, 44-53.
53. Cordeiro, M. F.; Guo, L.; Coxon, K. M.; Duggan, J.; Nizari, S.; Normando, E. M.; Sensi, S. L.; Sillito, A M.; Fitzke, F. W.; Salt, T. E.; Moss, S. E. Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo. Cell Death Dis., 2010, 1, e3.
54. Nichols, N.; D, B.; Finch, C.; Evidence for Apoptotic Cell Death In Alzheimer’s Disease. WE, H. Exp. Neurol., 1995, 133, 225-230.
55. Lee, A. G.; Martin, C. O. Neuro-ophthalmic findings in the visual variant of Alzheimer’s disease. Ophthalmology, 2004, 111, 376-380.
56. Tzekov, R.; Mullan M. Vision function abnormalities in Alzheimer disease. Surv. Ophthalmol., 2014, 59, 414-433.
57. Butter, C. M.; Trobe, J. D.; Foster, N. L.; Berent, S. Visual-Spatial Deficits Explain Visual Symptoms in Alzheimer’s Disease. Am. J. Ophthalmol., 1996, 122, 97-105.
58. Cronin-Golomb, A; Corkin, S.; Rizzo, J. F.; Cohen, J.; Growdon, J. H.; Banks, K. S. Visual dysfunction in Alzheimer’s disease: relation to normal aging. Ann. Neurol., 1991, 29, 41-52.
59. Armstrong, R. A. Alzheimer’s Disease and the Eye. J. Optom., 2009, 2, 103-111.
60. Hinton, D. R.; Sadun, A. A.; Blanks, J. C.; Miller, C. Optic-Nerve Degeneration in Alzheimer’s Disease. N. Engl. J. Med., 1986, 315, 485-487.
61. Blanks, J. C.; Hinton, D. R.; Sadun, A. A.; Miller, C. Retinal ganglion cell degeneration in Alzheimer’s disease. a. Brain Res., 1989, 501, 364-372.
62. Kesler, A.; Vakhapova, V.; Korczyn, A. D.; Naftaliev, E.; Neudorfer, M. Retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Clin. Neurol. Neurosurg., 2011, 113, 523-526.
63. Costa, R. A.; Skaf, M.; Melo, L.A.S.; Calucci, D.; Cardillo, J. a; Castro, J. C.; Huang, D.; Wojtkowski, M. Retinal assessment using optical coherence tomography. Prog. Retin. Eye Res., 2006, 25, 325-353.
64. Kromer, R.; Serbecic, N.; Hausner, L.; Froelich, L.; Aboul-Enein, F.; Beutelspacher, S. C. Detection of Retinal Nerve Fiber Layer Defects in Alzheimer’s Disease Using SD-OCT. Front. Psychiatry, 2014, 5, 22.
65. Gao, L.; Liu, Y.; Li, X.; Bai, Q.; Liu, P. Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer’s disease. Arch. Gerontol. Geriatr., 2015, 60, 162-167.
66. Lu, Y.; Li, Z.; Zhang, X.; Ming, B.; Jia, J.; Wang, R.; Ma, D. Retinal nerve fiber layer structure abnormalities in early Alzheimer’s disease: evidence in optical coherence tomography. Neurosci. Lett., 2010, 480, 69-72.
67. Parisi, V. Semin Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer’s disease. Ophthalmol., 2003, 18, 50-57.
68. Moreno-Ramos, T.; Benito-León, J.; Villarejo, A.; Bermejo-Pareja, Retinal nerve fiber layer thinning in dementia associated with Parkinson’s disease, dementia with Lewy bodies, and Alzheimer's disease. F. J. Alzheimers. Dis., 2013, 34, 659-664.
69. Paquet, C.; Boissonnot, M.; Roger, F.; Dighiero, P.; Gil, R.; Hugon, J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Neurosci. Lett., 2007, 420, 97-99.
70. Patton, N.; Aslam, T.; MacGillivray, J.; Pattie, A; Deary, I.; Dhillon, B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease. J. Anat., 2005, 206, 318-348.
71. Cheung, C. Y.-L.; Ong, Y. T.; Ikram, M. K.; Ong, S. Y.; Li, X.; Hilal, S.; Catindig, J.-A. S.; Venketasubramanian, N.; Yap, P.; Seow, D.; Chen, C. P.; Wong, T. Y. Microvascular network alterations in the retina of patients with Alzheimer’s disease. Alzheimers. Dement., 2014, 10, 135-142.
72. Frost, S.; Kanagasingam, Y.; Sohrabi, H.; Vignarajan, J.; Bourgeat, P.; Salvado, O.; Villemagne, V.; Rowe, C. C.; Macaulay, S. L.; Szoeke, C.; Ellis, K. a; Ames, D.; Masters, C. L.; Rainey-Smith, S.; Martins, R. N.; Group, A. R. Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease. Transl. Psychiatry, 2013, 3, e233.
73. Reitz, C.; Brayne, C.; Mayeux, R. Epidemiology of Alzheimer’s disease. Nat. Publ. Gr., 2011, 7, 1-16.
74. Witt, N.; Wong, T. Y.; Hughes, A. D.; Chaturvedi, N.; Klein, B. E.; Evans, R.; McNamara, M.; Thom, S. A. M.; Klein, R. Epidemiology of Alzheimer’s disease. Hypertension, 2006, 47, 975-981.
75. Al-Fiadh, A. H.; Farouque, O.; Kawasaki, R.; Nguyen, T. T.; Uddin, N.; Freeman, M.; Patel, S. K.; Burrell, L. M.; Wong, T. Y. Retinal microvascular structure and function in patients with risk factors of atherosclerosis and coronary artery disease. Atherosclerosis, 2014, 233, 478-484.
76. De Jong, F.; Schrijvers, E.; Ikram, M.; Koudstaal, P.; De Jong, P.; Hofman, A; Vingerling, J.; Breteler, M. Retinal vascular caliber and risk of dementia. Neurology, 2011, 76, 816-821.
77. Linsenmeier, R. A.; Padnick-Silver, L. Metabolic dependence of photoreceptors on the choroid in the normal and detached retina. Investig. Ophthalmol. Vis. Sci., 2000, 41, 3117-3123.
78. Parver, L. M. Temperature modulating action of choroidal blood flow. Eye (Lond)., 1991, 5 (Pt 2), 181-185.
79. Margolis, R.; Spaide, R. F. A Pilot Study of Enhanced Depth Imaging Optical Coherence Tomography of the Choroid in Normal Eyes. Am. J. Ophthalmol., 2009, 147, 811-815.
80. Ikuno, Y.; Kawaguchi, K.; Nouchi, T.; Yasuno, Y. Choroidal Thickness in Normal Eyes Measured Using Cirrus-HD Optical Coherence Tomography. Invest. Ophthalmol. Vis. Sci., 2010, 51, 2173-2176.
81. Manjunath, V.; Taha, M.; Fujimoto, J. G.; Duker, J. S. Choroidal Thickness in Normal Eyes Measured Using Cirrus-HD Optical Coherence Tomography. Am. J. Ophthalmol., 2010, 150, 325-329.
82. Gharbiya, M.; Trebbastoni, A.; Parisi, F.; Manganiello, S.; Cruciani, F.; D’Antonio, F.; De Vico, U.; Imbriano, L.; Campanelli, A.; De Lena, C.J. Choroidal thinning as a new finding in Alzheimer’s disease: evidence from enhanced depth imaging spectral domain optical coherence tomography. Alzheimer’s Dis., 2014, 40, 907-917.
83. Cho, A. R.; Choi, Y. J.; Kim, Y. T. Influence of choroidal thickness on subfoveal choroidal thickness measurement repeatability using enhanced depth imaging optical coherence tomography Influence of choroidal thickness on subfoveal choroidal thickness measurement repeatability using enhance. Eye, 2014, 28, 1151-1160.
84. Alonso-Caneiro, D.; Read, S.A; Collins, M.J. Automatic segmentation of choroidal thickness in optical coherence tomography. Biomed. Opt. Express, 2013, 4, 2795-2812.
85. Park, H.-Y. L.; Lee, N.-Y.; Shin, H.-Y.; Park, C. K. J. Analysis of macular and peripapillary choroidal thickness in glaucoma patients by enhanced depth imaging optical coherence tomography. Glaucoma, 2014, 23, 225-231.
86. Zhang, C.; Tatham, A. J.; Medeiros, F. A.; Zangwill, L. M.; Yang, Z.; Weinreb, R. N. Assessment of Choroidal Thickness in Healthy and Glaucomatous Eyes Using Swept Source Optical Coherence Tomography. PLoS One, 2014, 9.
87. Scinto, L. F. M.; Daffner, K. R.; Dressler, D.; Ransil, B. I.; Weintraub, S.; Mesulam, M.; Potter, H.; Ransil, B.; Rentz, D. A Potential Noninvasive Neurobiological Test for Alzheimer’ s Disease. Science (80-.). 1994, 266, 1051-1054.
88. Loupe, D. N.; Newman, N. J.; Green, R. C.; Lynn, M. J.; Williams, K. K.; Geis, T. C.; Edelhauser, H. F. Pupillary Response to Tropicamide in Patients with Alzheimer Disease. Ophthalmology, 1996, 103, 495-503.
89. Higuchi, S.; Matsushita, S.; Hasegawa, Y.; Muramatsu, T.; Arai, H. Pupillary response to tropicamide in Japanese patients with alcoholic dementia, Alzheimer’s disease, and vascular dementia. Exp. Neurol., 1997, 144, 199-201.
90. Granholm, E.; Morris, S.; Galasko, D.; Shults, C.; Rogers, E.; Vukov, B. Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer’s and Parkinson's disease. Int. J. Psychophysiol., 2003, 47, 95-115.
91. Kardon, R. H. Drop the Alzheimer’s drop test. Neurology 1998, 50, 588-591.
92. Iijima, A. Re-evaluation of tropicamide in the pupillary response test for Alzheimer’s disease. Neurobiol. Aging, 2003, 24, 789-796.
93. Sacks, B. E. N.; Smith, S. People with Down’s syndrome can be destinguished on the basis of cholinergic dysfunction. J. Neurol. Neurosurg. Psychiatry, 1989, 1294-1295.
94. Weksler, M. E.; Szabo, P.; Relkin, N. R.; Reidenberg, M. M.; Weksler, B. B.; Coppus, A. M. W. Alzheimer’s disease and Down's syndrome: treating two paths to dementia. Autoimmun. Rev., 2013, 12, 670-673.
95. O’Brien, R.; Wong, P. Amyloid precursor protein processing and alzheimer’s disease. Annu. Rev. Neurosci., 2011, 1987, 185-204.
96. Kosinski-Collins, M. S.; King, J. In vitro unfolding, refolding, and polymerization of human gammaD crystallin, a protein involved in cataract formation. Protein Sci., 2003, 12, 480-490.
97. Frederikse, P. H.; Ren, X. Lens Defects and Age-Related Fiber Cell Degeneration in a Mouse Model of Increased AβPP Gene Dosage in Down Syndrome. Am. J. Pathol., 2002, 161, 1985-1990.
98. Frederikse, P. H.; Garland, D.; Zigler, J. S.; Piatigorsky, J. Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. JBC, 1996, 271, 10169-10174.
99. Frederikse, P. H. Amyloid-like protein structure in mammalian ocular lenses. Curr. Eye Res., 2000, 20, 462-468.
100. Goldstein, L.E.; Muffat, J.A.; Cherny, R.A.; Moir, R.D.; Ericsson, M.H.; Huang, X.; Mavros, C.; Coccia, J.A.; Faget, K.Y.; Fitch, K.A.; Masters, C.L.; Tanzi, R.E.; Chylack, L.T.; Bush, A.I. Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer’s disease. Lancet, 2003, 361, 1258-1265.
101. Moncaster, J. A.; Pineda, R.; Moir, R. D.; Lu, S.; Burton, M. A.; Ghosh, J. G.; Ericsson, M.; Soscia, S. J.; Mocofanescu, A.; Folkerth, R. D.; Robb, R. M.; Kuszak, J. R.; Clark, J. I.; Tanzi, R. E.; Hunter, D. G.; Goldstein, L. E. Alzheimer’s disease amyloid-β links lens and brain pathology in down syndrome. PLoS One, 2010, 5.
102. Kerbage, C.; Sadowsky, C. H.; Jennings, D.; Cagle, G. D.; Hartung, P.D. Alzheimer’s disease diagnosis by detecting exogenous fluorescent signal of ligand bound to beta amyloid in the lens of human eye: An exploratory study. Front. Neurol., 2013, 4 MAY, 1-9.
103. Michael, R.; Rosandić, J.; Montenegro, G. A.; Lobato, E.; Tresserra, F.; Barraquer, R. I.; Vrensen, G. F. J. M. Absence of beta-amyloid in cortical cataracts of donors with and without Alzheimer’s disease. Exp. Eye Res., 2013, 106, 5-13.
104. Ho, C.; Troncoso, J. C.; Knox, D.; Stark, W.; Eberhart, C. G. Beta- Amyloid, Phospho-Tau and Alpha-Synuclein Deposits Similar to Those in the Brain Are Not Identified in the Eyes of Alzheimer’s and Parkinson's Disease Patients. Brain Pathol., 2012, 29, 997-1003.
105. Tian, T.; Zhang, B.; Jia, Y.; Li, Z. Promise and challenge: The lens model as a biomarker for early diagnosis of Alzheimer’s disease. Dis. Markers, 2014, 826503.
106. Masters, C. L.; Selkoe, D. J. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb. Perspect. Med., 2012, 2, a006262.
107. Seeman, P.; Seeman, N. Alzheimer’s disease: β -amyloid plaque formation in human brain. Synapse, 2011, 65, 1289-1297.
108. Hardy, J. A.; Higgins, G. A. Disease: Alzheimer’ s Cascade Hypothesis Amyloid. Science (80-.). 1992, 256, 184-185.
109. Perez, S. E.; Lumayag, S.; Kovacs, B.; Mufson, E. J.; Xu, S. Betaamyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer’s disease. Invest. Ophthalmol. Vis. Sci., 2009, 50, 793-800.
110. Ning, A.; Cui, J.; To, E.; Ashe, K. H.; Matsubara, J. Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest. Ophthalmol. Vis. Sci., 2008, 49, 5136-5143.
111. Koronyo-Hamaoui, M.; Koronyo, Y.; Ljubimov, A. V; Miller, C. A.; Ko, M. K.; Black, K. L.; Schwartz, M.; Farkas, D. L. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage, 2011, 54 Suppl 1, S204-S217.
112. Koronyo, Y.; Salumbides, B. C.; Black, K. L.; Koronyo-Hamaoui, Alzheimer’s disease in the retina: imaging retinal aβ plaques for early diagnosis and therapy assessment. M. Neurodegener. Dis., 2012, 10, 285-293.
113. Schön, C.; Hoffmann, N. A.; Ochs, S. M.; Burgold, S.; Filser, S.; Steinbach, S.; Seeliger, M. W.; Arzberger, T.; Goedert, M.; Kretzschmar, H. A; Schmidt, B.; Herms, J. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One, 2012, 7, e53547.
114. Gasparini, L.; Crowther, R. A.; Martin, K. R.; Berg, N.; Coleman, M.; Goedert, M.; Spillantini, M. G. Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability. Neurobiol. Aging, 2011, 32, 419-433.